Each year there are approximately 15M strokes that occur globally with 700,00 strokes occurring in the U.S. alone. Approximately 85% of all strokes are ischemic strokes, which occur when a blood clot blocks blood flow to the brain.
Currently, medication treatments for ischemic stroke are primarily limited to Tissue Plasminogen Activator (“TPA”) or blood thinners. However, these treatments are stroke type specific and cannot be given until the patient has received a CT scan to determine if the stroke is ischemic or haemorrhagic. Patients being treated with TPA must receive the drug within 3 hours of the injury. As a result, only 5% of stroke patients receive TPA.
The global stroke treatment market was valued at ~US$ 8 Bn in 2018 and is projected to grow at a CAGR of ~7% over the forecast period, the global stroke treatment market is expected to reach a value of ~US$ 15 Bn by the year 2027.
(in US$ Billions)
*According to a 2019 report from Transparency Market Research